Freenome, Inc. Common stock (FRNM) Stock Price

FRNMStock
$11.75
Market Cap$1.26B
P/E1507.52x
PEG Ratio—
Div yield—
Beta0.01

FRNM Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-27.89%
VGM Score12.86
P/E Ratio (Annual)1507.52x

FRNM Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026—-$2.59—

FRNM Analyst Recommendations

Sep 2026
4.29

Industry Peers — Health Services(30)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/E Ratio (Annual)Revenue Growth TTM (YoY)Operating Margin (TTM)ROE (TTM)Price
FRNMFreenome, Inc. Common stock
—FF1507.5x——-0.9%$11.75
NTRANatera, Inc. Common StockFAA—37.8%-10.7%-11.7%$393.44
DGXQuest Diagnostics Inc.CDB26.1x9.9%14.1%14.5%$235.00
LHLabcorp Holdings Inc.CDB29.4x6.4%10.4%11.6%$317.95
GHGuardant Health, Inc. Common StockFAB—42.7%-40.2%-246.6%$158.60
CAICaris Life Sciences, Inc. Common StockFAB—38.5%12.7%18.8%$30.56
RDNTRadNet, Inc. Common StockDCC1779.3x18.9%3.0%-1.9%$68.80
GRALGRAIL, Inc. Common StockDBB—23.1%-338.4%-15.9%$117.81
BLLNBillionToOne, Inc. Class A Common StockFFC621.1x—10.9%8.9%$98.12
VCYTVeracyte, Inc.DBC52.2x17.3%19.6%8.6%$43.12
CDNACareDx, Inc.DBA18.3x34.4%23.6%32.8%$64.00

About Freenome, Inc. Common stock

Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.